MYRIAD GENETICS INITIATES PHASE III CLINICAL TRIAL OF FLURIZAN IN ALZHEIMER'S DISEASE

Myriad Genetics has initiated enrollment in a Phase III human clinical trial of its lead therapeutic candidate, Flurizan (MPC-7869), in patients with Alzheimer's disease.

The Phase III trial is designed to determine Flurizan's ability to alter the course of cognitive decline and behavioral change in patients with Alzheimer's disease. The trial will be conducted in approximately 750 patients with mild-to-moderate Alzheimer's disease, at approximately 100 centers in the U.S.

The Phase III study is a double-blind, placebo-controlled trial, with randomization of patients at enrollment into one of three arms. Patients will be given 400 mg or 800 mg of Flurizan twice daily or placebo twice daily for the duration of the 12-month study period.